Table 3.
Locus | Gene | Number of SNPs per gene | p-value | Small molecule compound | Biotherapeutic | ADME | Drug in clinical trial | FDA approved drug |
---|---|---|---|---|---|---|---|---|
Chr1 | ST3GAL3 | 483 | 3.06E−12 | Yes | No | No | No | No |
KDM4A | 71 | 2.11E−11 | Yes | No | No | No | No | |
PTPRF | 225 | 5.06E−10 | Yes | No | No | Yes | Yes | |
TIE1 | 30 | 2.01E−08 | Yes | No | No | Yes | Yes | |
MPL | 12 | 4.69E−08 | Yes | Yes | No | Yes | Yes | |
SLC6A9 | 67 | 2.39E−07 | Yes | No | No | Yes | Yes | |
ARTN | 10 | 3.27E−06 | No | No | No | No | No | |
Chr4 | MANBA | 203 | 5.99E−08 | Yes | No | No | No | No |
Chr12 | KCNH3 | 40 | 4.23E−06 | Yes | No | No | Yes | Yes |
“p-value” column indicates the strength of association between a gene and ADHD
ADME: genes involved in the absorption, distribution, metabolism, and excretion of drugs; FDA: United States of America Food and Drug Administration; SNP: single nucleotide polymorphism